+289.3%
INTC vs MRNA
+511.3%
-222.0%
-41.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.5% | -2.2% | +6.7% | +4.5% |
| 7D | +7.1% | +5.5% | +1.6% | +7.0% |
| 30D | -5.2% | +158.7% | -163.9% | -10.5% |
| 3M | -14.3% | +182.1% | -196.4% | -22.5% |
| 6M | +110.2% | +151.8% | -41.6% | +94.5% |
| YTD | +159.6% | +393.6% | -233.9% | +106.9% |
| 1Y | +289.3% | +499.5% | -210.2% | +206.2% |
| All | +289.3% | +511.3% | -222.0% | +206.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling